House Panel To Subpoena AbbVie Documents On Price, Patent Tactics

By John Wilkerson / September 3, 2020 at 10:49 AM
The House Oversight Committee plans to subpoena AbbVie documents on how executives set prices for Humira, one of the world’s best-selling drugs, and the cancer drug Imbruvica, according to a release from Chair Carolyn Maloney (D-NY). The subpoena is part of an investigation started by the late Rep. Elijah Cummings (D-MD) in January of 2019. Cummings requested documents from a dozen companies on pricing practices, executive incentives, research and development spending and patent strategies. Of those companies, only AbbVie received...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.